Inotuzumab Ozogamicin
Acute Lymphoblastic Leukemia
Explore 247 assets in Acute Lymphoblastic Leukemia →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
antibody_drug_conjugate
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
71High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06985485CT.gov Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy | — | Recruiting | — | — | — |
NCT06861348CT.gov Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT | — | Not Yet Recruiting | — | — | — |
NCT06427330CT.gov Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT06087419CT.gov A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | — | Unknown | — | — | — |
NCT05748171CT.gov A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL | — | Recruiting | — | — | — |
NCT05687032CT.gov A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT05456698CT.gov Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT07238907CT.gov A Multi-center Retrospective Study of INO Treating B-ALL | — | Active Not Recruiting | — | — | — |
NCT05016947CT.gov Venetoclax Plus Inotuzumab for B-ALL | — | Active Not Recruiting | — | — | — |
NCT04747912CT.gov Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) | — | Recruiting | — | — | — |
Show 13 more trialsShow fewer
NCT03851081CT.gov Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia | — | Withdrawn | — | — | — |
NCT04307576CT.gov A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | — | Recruiting | — | — | — |
NCT03610438CT.gov Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia | — | Unknown | — | — | — |
NCT03856216CT.gov Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation | — | Terminated | — | — | — |
NCT03677596CT.gov A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients | — | Completed | — | — | — |
NCT03913559CT.gov Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT03488225CT.gov Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT03441061CT.gov Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease | — | Active Not Recruiting | — | — | — |
NCT03094611CT.gov Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT03104491CT.gov Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia | — | Recruiting | — | — | — |
NCT01564784CT.gov A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT01363297CT.gov Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia | — | Completed | — | — | — |
NCT01134575CT.gov CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Inotuzumab Ozogamicin (this asset) | The First Affiliated Hospital of Soochow University | Approved | BB · 69 |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Equine Atg | Instituto Nacional de Cancer, Brazil | P3 | BBB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BBB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P4 | BB |
| Asparaginase | Centre Hospitalier Universitaire de Nice | P4 | BB |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Methotrexate | Princess Maxima Center for Pediatric Oncology | P4 | BB |
+42 more in the Acute Lymphoblastic Leukemia cohort
Other indications for Inotuzumab Ozogamicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P4 | BB · 67 |
| B-Cell Non-Hodgkin Lymphoma | — | P2 | B · 62 |
| Central Nervous System Leukemia | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineBBB
- Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterBBB
- Equine AtgInstituto Nacional de Cancer, BrazilBBB
- Thioguanine AnhydrousSt. Jude Children's Research HospitalBBB
- Mercaptopurine AnhydrousDana-Farber Cancer InstituteBB
Citation
Floatz Terminal. Inotuzumab Ozogamicin in Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/inotuzumab-ozogamicin-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →